Activity |
Resource/URL |
Contact |
Funding |
Currently active initiatives for fundamental and translational research for influenza; accepting investigator-initiated grant applications in all areas of influenza research |
NIAID funding opportunities for influenza investigators |
Vaccines: David Cho, NIAID Antivirals: Amy Krafft, NIAID Basic research and diagnostics: Rachelle Salomon, NIAID Clinical trials: Sonnie Kim, NIAID |
Pre-Clinical Research |
Conduct prospective international and/or domestic animal influenza surveillance for the rapid detection and characterization of influenza viruses with pandemic potential
Conduct research to enhance understanding of the molecular, ecological, and/or environmental factors that influence pathogenesis, transmission, and evolution of influenza viruses; and characterize the protective immune response.
|
Centers of Excellence for Influenza Research and Surveillance (CEIRS) |
Diane Post, NIAID |
Evaluate compounds in vitro and in vivo for antiviral activity against influenza |
In Vitro Antiviral Screening Program
Animal Models for the Evaluation of Experimental Therapies and Vaccines
|
In vitro testing: Christopher Tseng, NIAID
In vivo testing: Heather Greenstone, NIAID |
Provide targeted screening and evaluation of potential therapeutic and prevention modalities for emerging infectious agents and bioterrorism pathogens using in vitro, small animal, and nonhuman primate models to test safety and efficacy |
In Vitro and Animal Models for Infectious Diseases
|
Judy Hewitt, NIAID |
Supports and accelerates development of therapeutic agents by providing preclinical drug development resources to the scientific community and industry partners |
Services for the Preclinical Development of Therapeutic Agents |
Beth Spinelli, NIAID |
The IEDB contains data related to antibody and T cell epitopes for humans, non-human primates, rodents, and other animal species. Detailed curation of existing antibody and T cell epitope information for numerous Influenza strains. Online analysis tools: Antibody and T cell epitope prediction algorithms, epitope conservancy, population coverage. |
Immune Epitope Database and Analysis Resource (non-Government link)
|
A. Deckhut Augustine, NIAID |
Custom synthesis and distribution of soluble MHC-peptide tetramer reagents that can be used to stain antigen-specific T cells. Influenza- related reagents: Custom synthesis of human, non-human primate and mouse MHC class I and human and mouse class II tetramers (peptide provided by investigator). Three pre-made human class II tetramers containing flu matrix peptides (DRB10101, DRB10401, DRB10404). |
NIH Tetramer Facility (non-Government link)
|
A. Deckhut Augustine, NIAID |
Clinical |
NIAID contracts to conduct clinical trials for influenza research |
NIAID’s Vaccine Treatment and Evaluation Units (VTEUs) |
Suzanne Murray, NIAID |
Multidisciplinary network that supports pre-clinical studies designed to provide proof-of-concept data to accelerate progression of candidate products to clinical evaluation. This contract also supports Phase I and Phase II clinical trials of vaccines and therapeutics against selected human viral respiratory pathogens, including influenza, development of relevant immunological assays, and human challenge studies with influenza viruses. |
Respiratory Pathogens Translational Research Services |
Linda Lambert, NIAID |
Provides regularly updated information about federally and privately supported clinical research in human volunteers. |
ClinicalTrials.gov |
|
Research Infra-Structure |
Conduct prospective international and/or domestic animal influenza surveillance for the rapid detection and characterization of influenza viruses with pandemic potential
Conduct research to enhance understanding of the molecular, ecological, and/or environmental factors that influence pathogenesis, transmission, and evolution of influenza viruses; and characterize the protective immune response |
Centers of Excellence for Influenza Research and Surveillance (CEIRS) |
Diane Post, NIAID |
Sequencing the complete influenza genome with rapid access of the genomic data through GenBank and the NCBI Influenza Virus Resource. Influenza Research Database and Bioinformatics Analysis tools, supported through NIAID Bioinformatics Resource Center, BioHealthBase. |
NIAID Influenza Genome Sequencing Project
Databases and Analysis Tools: BioHealthBase (non-Government link)
NCBI Influenza Virus Resource
|
Maria Y. Giovanni, NIAID
|
Apply state-of-the-art high-throughput structural biology technologies to characterize the three dimensional (3-D) atomic structure of targeted proteins from pathogens in the NIAID Category A-C priority lists and organisms causing emerging and re-emerging infectious disease, including H1N1 influenza. |
Structural Genomics Centers for Infectious Diseases |
Valentina Di Francesco, NIAID |
Conduct research projects to analyze, identify, quantify, model and predict the overall dynamics of the network of cellular molecular components of microbial organisms, including H5N1 influenza, and their interactions with the host cells. |
Systems Biology for Infectious Disease Research |
Valentina Di Francesco, NIAID |
Provides scientists with genomic resources and reagents such as microarrays, protein expression clones (including H1N1 Gateway® Entry Clones), genotyping and bioinformatics services to conduct functional genomics research on human pathogens and invertebrate vectors of infectious diseases. Also supports the training of scientists in the latest techniques in functional genomics and emerging genomic technologies. |
Pathogen Functional Genomics Resource Center (PFGRC)
|
Maria Y. Giovanni, NIAID |
Generating the three-dimensional structures for influenza polymerase proteins and deposit structural data into public protein database. |
Proteomics Resource Center (non-Government link)
|
Maureen Beanan, NIAID |
Provide reagents and information for studying influenza |
Biodefense and Emerging Infections Research Resources Repository |
Susan Peacock, NIAID |